Who is sponsoring NCT00720590?

NCT00720590 is sponsored by Indiana University.

What condition does NCT00720590 study?

NCT00720590 studies Endothelial Dysfunction.

What drugs are being tested in NCT00720590?

Interventions: Atazanavir, Lopinavir/ritonavir, Placebo.

What is the status of NCT00720590?

NCT00720590 is currently COMPLETED.

Last reviewed 2017-10-23 · How we verify

Effect of HIV-1 Protease Inhibitors on Endothelial Function and Glucose Metabolism in Normal, HIV-Uninfected Subjects: Atazanavir or Lopinavir/Ritonavir or Placebo

NCT00720590 NA COMPLETED

HIV protease inhibitors (PIs) are a class of antiretroviral drugs used to inhibit viral replication. They do so by interfering with a key step in the replication process. Some HIV PIs have been associated with an increased risk of adverse cardiovascular side effects. Further study is needed, however, to assess the full extent of effect of newer HIV PIs, including atazanavir and lopinavir/ritonavir, on cardiovascular disease risk. This study will compare the effects of atazanavir, lopinavir/ritonavir, and placebo on certain cardiovascular disease risk factors in healthy people without HIV.

Details

Lead sponsor	Indiana University
Phase	NA
Status	COMPLETED
Enrolment	30
Start date	2003-11
Completion	2006-10

Conditions

Endothelial Dysfunction

Interventions

Atazanavir
Lopinavir/ritonavir
Placebo

Primary outcomes

Leg blood flow response to the intra-femoral artery infusion of methacholine chloride — Measured at Week 4

Countries

United States